Aim      To evaluate trends in beta-blocker prescribing and incidence of possible reasons for beta-blocker administration, including arterial hypertension (AH), atrial fibrillation (AF), ischemic heart disease (IHD), and myocardial infarction, in participants of clinical studies enrolling patients with chronic heart failure with preserved ejection fraction (CHF-PEF).Material and methods  A systematic literature search was performed in the PubMed and EMBASE databases. The study included RCSs of pharmacological therapies for patients with CHF-PEF conducted from 1993 through 2019. Studies of beta-blocker efficacy or those including a specific population (CHF-PEF+IHD or CHF-PEF+AH, etc.) were excluded from the analysis. Baseline characteristics of patients, incidence rate of beta-blocker prescribing, and prevalence of AH, AF, IHD, and MI were recorded. Trends in prevalence of concomitant diseases and the proportion of patients using beta-blockers by the year of enrollment to the study were analyzed with the Mann-Kendall test.Results 14 RCSs of 718 selected publications completely met the inclusion and exclusion criteria. Beta-blocker prescribing significantly increased between 1993 and 2019 (tau=0.51; p=0.014) and reached 80 % in recent studies. Furthermore, prevalence of IHD, MI, AH, and AF did not significantly change among the RCS participants (p>0.05 for all). However, while for AH and AF, a tendency toward an increasing prevalence (tau=0.4; p=0.055 and tau=0.043; p=0.063, respectively) could be considered and became statistically significant for AF when the ALDO-DHF study was excluded from the analysis (tau=0.5; p=0.042), the MI prevalence tended to decrease (tau= -0.73; p=0.06).Conclusion      Beta-blocker prescribing to patients upon inclusion into RCSs for CHF-PEF has significantly increased for the recent 20 years while the incidence of formal reasons for beta-blocker administration (AF, AH, MI, IHD) did not significantly change.

Download full-text PDF

Source
http://dx.doi.org/10.18087/cardio.2020.6.n1062DOI Listing

Publication Analysis

Top Keywords

beta-blocker prescribing
16
heart failure
8
failure preserved
8
preserved ejection
8
reasons beta-blocker
8
beta-blocker administration
8
1993 2019
8
excluded analysis
8
prevalence ihd
8
ihd change
8

Similar Publications

This study evaluated initial antihypertensive drug prescription patterns in Indian healthcare settings. An observational, cross-sectional, prospective prescription registry analyzed prescriptions for 4723 newly diagnosed hypertension patients. Additionally, it investigated the extent to which physicians adhered to either European or Indian hypertension guidelines.

View Article and Find Full Text PDF

Eutectogel-Based Drug Delivery: An Innovative Approach for Atenolol Administration.

Pharmaceutics

December 2024

Dipartimento di Farmacia, Salute e Scienze della Nutrizione, Università della Calabria, Arcavacata di Rende, 87036 Cosenza, Italy.

Hypertension affects 32% of adults worldwide, leading to a significant global consumption of cardiovascular medications. Atenolol, a β-adrenergic receptor blocker, is widely prescribed for cardiovascular diseases such as hypertension, angina pectoris, and myocardial infarction. According to the Biopharmaceutics Classification System (BCS), atenolol belongs to Class III, characterized by high solubility but low permeability.

View Article and Find Full Text PDF

Medical and advanced heart failure therapies in Türkiye.

Turk J Med Sci

December 2024

Deputy Health Minister, Ministry of Health, Ankara, Turkiye.

Background/aim: Effective management of heart failure involves evidence-based use of multiple medications and their combinations. Furthermore, dosage escalation of the recommended medications is advised. In cases of advanced heart failure, long-term mechanical assistance devices or heart transplantation surgery may be necessary.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on lower urinary tract symptoms (LUTS) and the rising interest in phytomedicines as alternatives to traditional medications, especially with limited efficacy of current treatments.
  • A survey conducted with 300 patients revealed that a significant portion (41%) of those on medication for LUTS were also using phytomedicines, which showed good tolerability despite lower efficacy ratings.
  • Patients expressed a desire for insurance coverage for phytomedicines, highlighting a shift toward individualized treatment options and the importance of patient empowerment in the decision-making process.
View Article and Find Full Text PDF

Evaluation of Prescription Pattern of Antihypertensives and Its Compliance with Joint National Committee 8 Guidelines in Hospital Setting.

J Assoc Physicians India

December 2024

Senior Consultant, Interventional Cardiologist, and Electrophysiologist, Department of Cardiology, Aditya Birla Memorial Hospital, Pune, Maharashtra, India.

Globally, hypertension is a major noncommunicable disease that contributes to significant fatalities and morbidity. Evaluation of trends in the prescription of antihypertensives and their adherence to the Joint National Commission 8 (JNC 8) recommendations can provide perspective on the dissemination of local and international guidelines in real-world clinical practice. An ambispective observational study was conducted over a duration of 6 months.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!